AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement Bristol-Myers Squibb Business and Allergan, Inc. today announced a worldwide agreement for the development and commercialization of AGN-209323, a Phase II-ready, administered small molecule in clinical advancement for orally neuropathic pain. The agreement encompasses all potential indications except ophthalmology indications for items formulated for local delivery to the attention, where Allergan will retain certain privileges. Bristol-Myers Squibb shall make an upfront payment of $40 million, potential AGN-209323 related development – and regulatory-based milestone payments of up to $373 million, and royalty payments on worldwide sales.D., executive vice president, Research & Development and Chief Scientific Officer, Allergan.This subgroup is certainly seen as a a 5q deletion concerning 5q31, bone marrow erythroid hyperplasia, atypical megakaryocytes, refractory anemia, and an indolent clinical course. 8,9 Apart from bone marrow transplantation, no curative treatment has been created for myelodysplastic syndromes. Recently, the thalidomide analogue lenalidomide10 has been proven to induce durable erythroid responses in patients with myelodysplastic syndromes; in such individuals, transfusion independence and complete cytogenetic remissions are observed frequently.11-13 However, 50 percent of these patients have medical and cytogenetic relapse after 2 to 3 3 years of treatment, indicating that lenalidomide might not be curative in such patients and raising the chance of ongoing clonal evolution toward acute myeloid leukemia during treatment.11,12,14-16 The del myelodysplastic syndrome involves the minor multipotent stem-cell compartment myelodysplastic syndrome that was in total scientific and cytogenetic remission.